Navigation Links
FDA Approves New Test To Help Determine if Breast Cancer Patients Are Candidates for Herceptin Treatment
Date:6/14/2011

samples from 510 patients with breast cancer. This study showed that the test was effective in confirming that a patient's tumor sample contained more than the normal number of copies of the HER2 gene in 96 percent of the HER2 positive tumor samples. Patients with more than the normal number of copies of the HER2 gene are considered candidates for Herceptin therapy.

The study also showed that the test was effective at excluding the possibility that more than the normal number of copies of the HER2 gene were present in 92.3 percent of the HER2 negative tumor samples. Patients who do not have more than the normal number of copies of the HER2 gene are typically not candidates for Herceptin therapy. The ability to identify patients who are HER2-positive is a useful tool for physicians who may be considering treatment with Herceptin for their breast cancer patients.

Breast cancer is the second leading cause of cancer-related death among women. An estimated 207,090 new cases of breast cancer were diagnosed in the United States during 2010 and about 39,840 women died from the disease, according to the National Cancer Institute. About 20 percent of women diagnosed with breast cancer are HER2-positive.

Tucson, Ariz.-based Ventana Medical Systems manufactures the Inform Dual ISH test. Herceptin is marketed by South San Francisco based-Genentech, a member of the Roche Group.

For more information:

FDA: Medical Devices

http://www.fda.gov/MedicalDevices/default.htm

FDA: Device Approvals and Clearances

http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/default.htm

NCI: Breast Cancer

http://www.cancer.gov/cancertopics/types/breast

<
'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)...  Xcelience, a contract development and manufacturing organization ... structured cash investment in Powdersize, a ... and powder size classification within the pharmaceutical industry.  ... simultaneously adding a complete set of particle size ... "As we continue to build our ...
(Date:7/31/2015)... July 31, 2015 Egalet Corporation (Nasdaq: ... pharmaceutical company focused on developing, manufacturing and marketing ... its previously announced underwritten public offering of 7,666,667 ... offering price of $11.25 per share. The shares ... shares issued upon the exercise in full by ...
(Date:7/31/2015)... and SAN DIEGO , ... its parent company Eisai Co., Ltd. (Headquarters: ... , "Eisai") and Halozyme Therapeutics, Inc. (Headquarters: ... Helen Torley , "NASDAQ: HALO") have signed a ... name: Halaven ® , "eribulin") in combination with Halozyme,s ...
Breaking Medicine Technology:Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6
... Shire plc (LSE: SHP, NASDAQ: SHPGY ... on the approval status and availability of ProAmatine® (midodrine ... orthostatic hypotension (SOH).  Shire has engaged in consistent dialogue ... the past 12 months in the hopes of either ...
... ideas are coming out of the small, island nation of ... Unit says for a country of its size, New Zealand ... "New Zealanders are known for their ingenuity—especially in creating ... push the envelope," says Marta Mager, Regional Director Americas for ...
Cached Medicine Technology:Shire Provides Update on ProAmatine® (midodrine HCl) 2Shire Provides Update on ProAmatine® (midodrine HCl) 3Shire Provides Update on ProAmatine® (midodrine HCl) 4Cool New Zealand Inventions 2Cool New Zealand Inventions 3
(Date:8/3/2015)... Park, NJ (PRWEB) , ... August 03, 2015 ... ... pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” ... software architects, engineers and technology leaders from healthcare organizations with access to the ...
(Date:8/3/2015)... ... August 03, 2015 , ... A July 9 article from USA ... recent years, according to the American Dental Association. According to a study by the ... from 1.1 million in a single year to 2.2 million a year. Dentists and ...
(Date:8/3/2015)... ... 2015 , ... Illinois Health & Science (IHS) has completed the purchase of ... all of IBAM NA’s cyclotron sites and research and development facilities. , ... as well as a large manufacturing hub in Noblesville, Indiana,” said Ken Smithmier, President ...
(Date:8/3/2015)... ... , ... Constantin Vasilica, 48 from Romania wanted to have an alternative healing ... years of suffering and using medications with strong side effects. This had already forced ... time off or wait longer hours in the waiting rooms. Instead, he went home ...
(Date:8/3/2015)... , ... August 03, 2015 ... ... a leading provider of medical information, risk management and investigative services, has ... and direction toward focused, expert information solutions that improve business outcomes for ...
Breaking Medicine News(10 mins):Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2
... named Jim Bohnsack vice,president of healthcare information solutions, a ... in the Western region of the United States. , ... president of healthcare,for TransUnion. , ... relationships,with key supporting institutions and organizations will be an ...
... will see Japan,s Trinity Design Corporation Ltd, becoming a reseller and ... already negotiated its first Rhapsody sale with the Kobe Circulation Clinic, ... quality medical care. , ... Auckland, NZ (PRWEB) ...
... LLP, founded in 1968, has successfully represented victims of negligence, personal ... , ... (PRWEB) January 6, 2008 -- Smiley & ... personal injury, wrongful death and medical malpractice for over 40 years. ...
... knew there had to be a better way. He and ... how best to engage patients with chronic diseases in effective ... Chronic Care Model. More than 1,500 U.S. and international medical ... evidence on how the Model performs in practice confirms that ...
... Technology Company today announces the award of a network IP-Based ... ... Washington, D.C. (PRWEB) December 15, 2008 -- ... Notification Technology Company, today announces the award of a network ...
... and surgeon medical liability, launched its first Southeast Legal Summit ... have the most current information regarding the defense of medical ... ... California (Vocus) December 17, 2008--- The Doctors Company , ...
Cached Medicine News:Health News:TransUnion Names New Vice President of Healthcare Information Solutions 2Health News:Orion Health Signs Trinity Design for Japanese Market 2Health News:Orion Health Signs Trinity Design for Japanese Market 3Health News:Prominent New York City Personal Injury Law Firm Founded in 1968 Stays at the Cutting Edge with Launch of Video-Based Website 2Health News:Chronic Care Model helps improve people’s health and care 2Health News:Chronic Care Model helps improve people’s health and care 3Health News:Berkshire Medical Center Selects Desktop Alert for Mass Notification Solutions 2Health News:Berkshire Medical Center Selects Desktop Alert for Mass Notification Solutions 3Health News:Berkshire Medical Center Selects Desktop Alert for Mass Notification Solutions 4Health News:The Doctors Company Launches Southeast Legal Summit to Provide Industry's Best Claims Defense for Physicians 2
... II (Low Melt), A low temperature ... melting temperature , Optimal for in-gel restriction ... forms a very manageable clear gel that ... Melts at approximately 65°C and remains fluid ...
... for molecular screening that improves resolution of small ... are:, High resolution of PCR and DNA ... of the gel, enhancing visibility. , Better handling ... structure and higher gel strength. The chances of ...
... Molecular Biology Grade, is used ... nucleic acids. It can be ... from 0.2 to 40 kb., ... is tested and certified to ...
Inquire...
Medicine Products: